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Urodilatin belongs to the natriuretic peptide family and
exerts its pharmacological effects via binding to the partic-
ulate guanylate cyclase A inducing intracellular increase of
cyclic guanosine monophosphate (cGMP). Urodilatin is
synthesized in the kidney and exhibits vasodilating, diu-
retic/natriuretic, and inhibitory effects on the renin-angi-
otensin-aldosterone-system. Ularitide is a synthetic
version of urodilatin. Based on its pharmacological pro-
file, Ularitide may present an ideal drug for the treatment
of decompensated congestive heart failure (DHF). We
investigated the pharmacodynamic effects of Ularitide in
SIRIUS I (pilot project in 24 patients) and in SIRIUS II
(proof-of-concept study) in 221 patients with DHF (inclu-
sion criteria: CI ≤ 2.5 l/min per m2, mean PCWP ≥ 18
mmHg). DHF patients were randomized equally to
receive 7.5, 15, or 30 ng/kg/min Ularitide or placebo by
continuous infusion over 24 hours. Ularitide significantly
reduced right and left ventricular filling pressures in both
studies. In SIRIUS II, PCWP significantly decreased at 6
hours: 7.5 ng: -6.5 ± 7.2; p < 0.05; 15 ng: -10.5 ± 6.3; p <
0.01; 30 ng: -10.1 ± 5.7; p < 0.01; placebo: -4.4 ± 6.1. Dys-
pnea score improved at 6 and 24 hours at all dose levels
compared to placebo. The two higher Ularitide dose
groups significantly decreased SVR. That produced an
increase in cardiac index: placebo: 0.1 ± 0.3; 7.5 ng: 0.2 ±
0.4; p < 0.05; 15 ng: 0.3 ± 0.4; p < 0.05; 30 ng: 0.4 ± 0.5;
p < 0.01. Haemodynamic improvement was accompanied
by a significant reduction of elevated NT-proBNP in the
15 and 30 ng groups compared to placebo at 24 hours (p
< 0.05). Systolic and diastolic blood pressure dose-
dependently decreased in the two higher ularitide groups
and diastolic BP decreased in all ularitide groups, while
heart rate was unchanged. Main adverse events through
day 3 were dose-dependent decreases in blood pressure/
hypotension. Serum creatinine levels were unchanged
during and over 2 days after end of ularitide infusion.
Mortality rate through day 30 was higher in the placebo
compared to ularitide 30 ng/kg/min group (p < 0.05).
There were no differences in serious adverse events among
the four treatment groups.
Conclusion
Ularitide infusions for 24 hours were well tolerated and
resulted in dose-dependent favourable clinical and
haemodynamic effects. Ularitide may have potential for
the treatment of patients with DHF.
from 3rd International Conference on cGMP Generators, Effectors and Therapeutic Implications
Dresden, Germany. 15–17 June 2007
Published: 25 July 2007
BMC Pharmacology 2007, 7(Suppl 1):S11 doi:10.1186/1471-2210-7-S1-S11
<supplement> <title> <p>3<sup>rd </sup>International Conference on cGMP Generators, Effectors and Therapeutic Implications</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1471-2210-7-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.biomedcentral.com/1471-2210/7/S1/S11
© 2007 Mitrovic; licensee BioMed Central Ltd. 
